Immunic reports new data from phase 2 emphasis trial of vidofludimus calcium in relapsing-remitting multiple sclerosis supporting the drug's neuroprotective potential

– data show encouraging signals for vidofludimus calcium for preventing or delaying confirmed disability worsening – – virtual multiple sclerosis r&d day to be held today, november 17, 2022 at 11:00 am et – new york , nov. 17, 2022 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today reported newly available data from its phase 2 emphasis trial of lead asset, vidofludimus calcium (imu-838), in relapsing-remitting multiple sclerosis (rrms). long-term open-label treatment with vidofludimus calcium was associated with a low rate of confirmed disability worsening over time, and compares favorably to historical trial data for currently available multiple sclerosis (ms) medications.
IMUX Ratings Summary
IMUX Quant Ranking